/LPCN

LPCN Stock - Lipocine Inc.

Q: What is the analyst price target for LPCN?

Analyst price target information is not currently available for LPCN.

Q: What is LPCN's market cap?

Market capitalization information is not currently available for LPCN.

Healthcare|Biotechnology|NASDAQ

$4.25+1.19%

+$0.05 (+1.19%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+135.3%upside

Target: $10.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for LPCN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.03

52W High$5.50

52W Low$2.52

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$11.20M	$-2,850,818	$500,000	$16.14M	N/A
Gross Profit	$11.20M	$-13,026,069	$-8,056,888	$8.48M	N/A
Gross Margin	100.0%	456.9%	-1611.4%	52.5%	N/A
Operating Income	$-1,155,035	$-17,930,957	$-12,119,375	$3.15M	$-17,996,264
Net Income	$8,352	$-16,352,082	$-10,758,636	$-634,399	$-20,964,819
Net Margin	0.1%	573.6%	-2151.7%	-3.9%	N/A
EPS	$0.00	$-3.14	$-2.15	$-0.19	$-6.46

Company Overview

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Visit Website

Earnings History & Surprises

LPCN

Beat Rate

39%

Last 18 quarters

Avg Surprise

-71.1%

EPS vs Estimate

Beats / Misses

7/7

4 met exactly

Latest EPS

$-0.59

Q4 2025

EPS Surprise History

Q1 24

+20.8%

$-0.42vs$-0.53

Q2 24

+197.1%

$0.66vs$-0.68

Q3 24

+28.2%

$-0.56vs$-0.78

Q4 24

+8.3%

$-0.44vs$-0.48

Q1 25

+182.5%

$0.33vs$-0.40

Q2 25

0.0%

$-0.35vs$-0.35

Q3 25

0.0%

$-0.41vs$-0.41

Q4 25

-5.4%

$-0.59vs$-0.56

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Mar 12, 2026	$-0.60	—	—	—
Q4 2025	Nov 6, 2025	$-0.56	$-0.59	-5.4%	✗ MISS
Q3 2025	Aug 5, 2025	$-0.41	$-0.41	0.0%	= MET
Q2 2025	May 8, 2025	$-0.35	$-0.35	0.0%	= MET
Q1 2025	Mar 13, 2025	$-0.40	$0.33	+182.5%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.48	$-0.44	+8.3%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.78	$-0.56	+28.2%	✓ BEAT
Q2 2024	May 9, 2024	$-0.68	$0.66	+197.1%	✓ BEAT
Q1 2024	Mar 7, 2024	$-0.53	$-0.42	+20.8%	✓ BEAT
Q4 2023	Nov 8, 2023	$-0.57	$-1.27	-122.8%	✗ MISS
Q3 2023	Aug 10, 2023	$-0.64	$-0.68	-6.3%	✗ MISS
Q2 2023	May 11, 2023	$-0.42	$-0.68	-61.9%	✗ MISS
Q1 2023	Mar 10, 2023	$0.03	$-0.51	-1800.0%	✗ MISS
Q4 2022	Nov 9, 2022	$-0.51	$-0.51	0.0%	= MET
Q3 2022	Aug 8, 2022	$-0.68	$-0.68	0.0%	= MET
Q2 2022	May 9, 2022	$-0.34	$-0.68	-100.0%	✗ MISS
Q1 2022	Mar 9, 2022	$-0.85	$2.55	+400.0%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.85	$-0.51	+40.0%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.85	$-1.36	-60.0%	✗ MISS